Administration of 1,2-dimethylhydrazine (DMH) induces intestinal epithelial tumors in mice. Increased numbers of mast cells have been reported to occur both within and near a variety of different neoplasms, including DMHinduced intestinal tumors. We investigated the role of the tyrosine kinase receptor, c-kit, and mast cells, in this model by administering DMH to c-kit mutant mast cell-deficient mice and the congenic normal mice. We attempted to induce colonic tumors by administering DMH (20 mg/kg body weight, s.c., weekly for 20 weeks) to
Mast cells can produce a wide variety of biologically active products, including histamine, serotonin (in murine rodents), heparin and other proteoglycans, many neutral proteases, several products of arachidonic acid metabolism via the 5-lipoxygenase or cyclooxygenase pathways, and a large number of cytokines, chemokines and growth factors. [1] [2] [3] [4] [5] Many of these mast cell-associated products have been shown to influence various aspects of tumor biology, and several types of tumors in both humans (eg, adenocarcinomas of the breast, pancreas, stomach and lung [6] [7] [8] [9] ) and experimental animals (eg, squamous cell carcinoma 10 ) have been reported to exhibit increased numbers of mast cells; however, the net effect of mast cells on the development and progression of specific tumors has been difficult to assess. [11] [12] [13] [14] [15] [16] This, in part, probably reflects the complexity of the underlying biology: different mast cell-associated products may have positive or negative effects on different aspects of tumorigenesis or tumor progression.
Several groups have used genetically mast celldeficient mice (usually, WBB6F1-Kit W /Kit W-v [W/W v ] mice) and the congenic normal WBB6F1-Kit þ / þ [ þ / þ ]) mice to search for specific effects of mast cells on the development or progression of particular experimental tumors. Using this approach, some groups have reported an increased susceptibility to tumors in mast cell-deficient mice in certain model systems, [17] [18] [19] while others reported that mast cell-deficient mice exhibited delayed tumor-associated angiogenesis and/or reduced tumor size and metastasis compared to the corresponding wild-type mice. 10, 20, 21 One explanation of these apparently discordant findings is that the net contribution of mast cells to different aspects of tumor biology in vivo can be quite variable, and may critically depend on the model system investigated. In the present study, we used W/W v and congenic wild-type ( þ / þ ) mice in an attempt to assess whether mast cells might contribute to the development of 1,2-dimethylhydrazine (DMH)-induced colonic epithelial tumors. We selected this model system because: (1) many colorectal carcinomas in humans are thought to arise as a result of the adenoma-carcinoma sequence; 22 (2) the colon carcinogen DMH can induce the development of colonic adenomas in mice, with subsequent development of dysplasia and, finally, colonic adenocarcinomas; [23] [24] [25] and (3) increased numbers of mast cells have been reported in both DMH-induced preinvasive colonic adenocarcinomas in mice 26 and DMH-induced colonic adenocarcinomas in rats. 27 Moreover, no previous report used genetically mast cell-deficient mice to investigate the potential contribution of mast cells to the development of intestinal tumors, whether induced by DMH or reflecting other pathogenetic pathways of tumor development.
We found that WBB6F1-þ / þ mice were significantly more susceptible to the development of DMH-induced colonic epithelial neoplasms than were the congenic c-kit mutant WBB6F1-W/W v mast cell-deficient mice. In addition, W/W v mice that had received i.v. injection of bone marrow cells from the congenic þ / þ mice (to repair the mast cell deficiency of the W/W v recipients) exhibited a susceptibility to the development of DMH-induced colonic tumors that was similar to that of the wildtype mice. These findings show that genetic impairment of c-kit function reduces the susceptibility of mice to DMH-induced colonic tumors, and prove that defects in bone marrow-derived cells in the W/W v mice contribute significantly to this result. Our findings also are consistent with the possibility that mast cells contribute to the development of DMH-induced colonic epithelial neoplasms in mice.
Materials and methods

Mice
Female 5-7-week-old C57BL6/J mice (n ¼ 64), genetically mast cell-deficient WBB6F1-Kit W /Kit
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were kept in community cages at light periods of 12 h, and were fed water and mouse chow ad libitum. Citrobacter rodentium infection was excluded by regular monitoring of the mouse colonies in the Stanford Laboratory Animal Facility. The Helicobacter status of the colonies has not routinely been monitored. All animal care and experimentation was conducted in accord with current National Institutes of Health and Stanford University Institutional Animal Care and Use Committee guidelines. All experiments were performed with age-matched female mice.
Bone Marrow Transplantation
To repair their mast cell deficiency, some W/W v mice (female, 5-7 weeks old, n ¼ 6, Table 1 ) received an i.v. injection of 2 Â 10 7 freshly isolated þ / þ mouse bone marrow cells. Briefly, bone marrow cells were flushed from the femurs of þ / þ mice with cold Dulbeccó s minimal essential medium (DMEM, Gibco BRL, Grand Island, NE, USA). Viable cells were counted with trypan blue exclusion and 2 Â 10 7 cells were resuspended in 200 ml of DMEM and injected via a tail vein. Control animals received 200 ml of DMEM without cells.
Induction of Colonic Tumors with DMH
Mice received weekly s.c. injections of either DMH, 20 mg/kg body weight, in NaH 2 CO 3 -buffered EDTA, 1 mM (pH 6.5), or the vehicle alone (only C57BL/6J, n ¼ 13), for 20 consecutive weeks. Treatment was started at the age of 5-7 weeks. At 30 weeks after the beginning of treatment, mice were killed by CO 2 inhalation. The peritoneal cavity was opened, the colon removed, the colonic mucosa was exposed with a longitudinal incision and the colonic mucosa was investigated under a stereomicroscope at a magnification of Â 5-30. Tumor occurrence and tumor size (observed with a stereomicroscope and measured with a ruler) were documented. Tissue was harvested and fixed in either Carnoy's fixative (ethanol 60%, chloroform 30%, acetic acid 10%), Karnovsky's fixative (paraformaldehyde 2%, glutaraldehyde 2.5%, CaCl 2 0.025%, cacodylate buffer 0.1 M) or 4% paraformaldehyde in phosphate-buffered saline (PBS).
Histology and Histochemistry
For quantification of colonic mast cells, 5 mm sections from Carnoy's-fixed tissues were stained with alcian blue/eosin or toluidine blue and examined under light microscopy at a Â 400 or Â 1000 magnification. To assess mast cell degranulation, 0.5 mm Epon-embedded sections of Karnovsky's fixed tissues were stained with Giemsa and examined under light microscopy at Â 1000 magnification. To assess whether mast cells contained significant amounts of heparin, 4 mm Carnoy's-fixed sections were deparaffinized, rinsed in distilled water acidified with 1% citric acid to pH 4.0, stained for 10 s with 0.02% berberine sulfate solution acidified with 1% citric acid to pH 2.5. 28, 29 Slides were briefly rinsed in distilled water (pH 4.0), excess fluid was removed and slides were mounted with glycerol and examined immediately with a fluorescence microscope. Berberine sulfate binds to heparin in mast cell cytoplasmic granules, and the berberine sulfate-positive cells exhibit a bright yellow fluorescence, in a cytoplasmic pattern, when examined under a fluorescent microscope. 28 Carnoy's-fixed 4 mm sections of skin from C57BL/6J mice served as positive control for berberine sulfatepositive mast cells.
Assessment of Colonic Epithelial Cell Proliferation
Age-and gender-matched þ / þ and W/W v mice received either DMH (20 mg/kg of body weight in NaH 2 CO 3 -buffered EDTA, 1 mM, pH 6.5). or the vehicle alone, s.c., and were killed 6 h after the injection. At 1 h before killing, mice received i.p. injections of 30 mCi [ 3 H]thymidine (Perkin Elmer Life Science, Boston, MA, USA). After killing the mice by inhalation of CO 2 , an B1 cm long piece of the descending colon was removed. Adjacent tissue was carefully removed and the tissue sample was weighed on a scale. The samples were incubated overnight at 371C in 500 ml trypsin-EDTA. The samples were then homogenized and transferred to scintillation fluid, mixed well and counted in a betacounter. The ratio of cpm/mg tissue was calculated.
Statistical Analysis
Data obtained from the different experiments were analyzed using the software Statview Version 5.0. 1 for Macintosh and PC. The incidence of tumor development in various groups was compared using w 2 -test. The numbers of adenomas and mast cell numbers/mm 2 of tissue were compared using the unpaired Student's t-test or Mann-Whitney U-test. A P-value below 0.05 was considered to be significant. Unless otherwise specified, all data are presented as mean7s.e.m. or mean þ s.e.m.
Results
DMH-Induced Colonic Tumors were Associated with Increased Numbers of Mast Cells
Histological examination revealed significantly increased numbers of mast cells at sites of tumor development compared to normal appearing control tissue (Figure 1a -e). Mast cells occurred mainly in the vascularized areas of the tumors, often in close proximity to blood vessels, although occasional mast cells were found in the epithelial mucosa of the tumors. Epon-embedded, 1-mm-thick, Giemsastained sections (Figure 1d ) showed that most mast cells exhibited small dark cytoplasmic granules, as Almost all of the WBB6F1-þ / þ mice treated with DMH developed intestinal tumors (97%) ( Table 1) , with a mean of 3.570.5 tumors per mouse. Histological sampling of the epithelial tumors indicated that none of the WBB6F1-þ / þ mice had developed adenocarcinomas that exhibited invasion through the muscularis mucosae, and none of the mice exhibited gross evidence of metastatic disease. However, several of the adenomatous polyps exhibited areas of slight to severe atypia, and in a few cases the lesions had areas of intraepithelial adenocarcinoma. These findings are similar to those that , in mast cell-deficient W/W v mice (normal mucosa, n ¼ 7; tumors, n ¼ 7) and in W/W v mice that had been repaired of their mast cell deficiency by whole bone marrow transplantation (BM-W/W v mice) at 5-7 weeks of age (normal mucosa, n ¼ 6; tumors, n ¼ 13). Data were analyzed using the unpaired Student's t-test (***Po0.005).
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Some mouse strains, such as CF1, BALB/c or SWR/J, have been reported to express a higher susceptibility to DMH-induced tumor development than do WBB6F1-þ / þ mice. 24, 30, 31 However, when we administered DMH to female C57BL/6 (ie, 'B6') mice (that are semisyngeneic with the WBB6F1 mice used in this study), 59% of the 64 mice tested developed at least one tumor (Table 1) , that ranged in size from 1 to 4 mm. The rate of development of tumors in the C57BL/6 mice was significantly less than that in the WBB6F1-þ / þ mice (Po0.0001). Thus, the rate of tumor development in response to DMH in WBB6F1-þ / þ mice, while lower than that reported for mice of the CF1, BALB/c or SWR/J strains, was significantly higher than that in the C57BL/6 strain, that is considered as having 'medium' susceptibility to the tumorigenic effects of this agent. 24, 31 Moreover, mast cell-deficient W/W v mice are only available on the mixed genetic background (WB/REJ Â C57BL/6J) and are not available on highly susceptible genetic backgrounds such as CF1. Accordingly, we performed the remainder of our studies entirely with WBB6F1 mice. Figure 4 ). As expected, no mast cells were detected histologically in either the normal appearing gut tissue or in any of the tumors that developed in the W/W v mice (Figure 2 ). 
v mice exhibited a susceptibility to DMH-induced tumors that was similar to that of the wild-type ( þ / þ ) mice, and that was significantly greater than that of the mast cell-deficient W/W v mice (Po0.0005) (Figure 4) . All of the bone marrow-reconstituted W/W v mice developed intestinal tumors, with a mean of 2.270.4 v mice) at 5-7 weeks of age. Data were pooled from three independent experimental groups that gave similar results, and the data were analyzed using the unpaired Student's t-test (*Po0.05, **Po0.01 and ***Po0.005; n.s. ¼ P40.05). (Figure 2) . Furthermore, mast cell numbers at various anatomical sites (ear skin, stomach, colon) of the þ / þ BM-W/W v mice were similar to those in wild-type WBB6F1-þ / þ mice (data not shown).
Histological examination of tumors and the adjacent non-neoplastic colon mucosa in a total of 18 individual specimens from six c-kit mutant mast cell-deficient W/W v mice, eight congenic wild-type mice, and two W/W v mice which had received bone marrow cells derived from the congenic wild-type mice ( þ / þ BM-W/W v mice), also showed variable but generally modest focal inflammatory infiltrates in some areas of the tumors, consisting primarily of lymphocytes with occasional plasma cells and granulocytes. The non-neoplastic colon mucosa adjacent to the tumors generally exhibited either minimal or no inflammation.
DMH Reduces Colonic Epithelial Cell Proliferation
In Vivo to a Similar Extent in WBB6F1-þ / þ and W/W v Mice
Acute changes that have been associated with DMH exposure include an abrupt reduction in colonic DNA synthesis that is followed by an increasing occurrence of aberrant nuclei in the epithelial layer. 32 To assess whether the presence of mast cells or other c-kit-related factors might alter the effect of DMH treatment on the proliferation of colonic epithelium, we investigated the acute effects of DMH treatment on DNA synthesis in specimens of colon of W/W v and þ / þ mice. As previously reported, a significantly decreased uptake of tritium-labeled thymidine was detected in DMHtreated þ / þ mice in comparison to vehicle-treated þ / þ mice (Po0.05) ( Figure 5) . 32 The same effect was detected in W/W v mice. Indeed, there were no statistically significant differences between þ / þ and W/W v mice for [ 3 H]thymidine incorporation values for either control (vehicle-treated) or DMHtreated mice ( Figure 5 ). This experiment suggests that the differences in adenoma development after DMH treatment of W/W v mice vs þ / þ control mice probably do not reflect significant differences in the bioavailability of DMH in mice of the two genotypes.
Discussion
Our data clearly demonstrate that WBB6F1-W/W v mice are substantially less susceptible than the congenic wild type (WBB6F1-þ / þ ) mice to the development of colonic epithelial neoplasms in response to DMH treatment in the model system tested. We found that W/W v mice that had been repaired of their mast cell deficiency by adoptive transfer of bone marrow cells from the congenic þ / þ mice had a susceptibility to DMH-induced tumor development that was very similar to that of the wild-type mice. Thus, it is clear that a bone marrow-derived cell type (or types) is/are responsible for the increased susceptibility of wild-type mice to DMH-induced tumor development, as compared to c-kit mutant W/W v mice. However, our findings are less conclusive concerning which specific hematopoietic cell lineages in the W/W v mice are responsible for this effect. In the þ / þ mice or þ / þ bone marrow-reconstituted W/W v mice, the DMH-induced tumors contained large numbers of mast cells, and numbers of mast cells were greater in large tumors than in the smaller tumors. Finally, the tumors that did develop in the genetically mast cell-deficient W/W v mice included a larger proportion of small lesions (o1 mm) than did those that developed in either the þ / þ mice or the þ / þ bone marrow-reconstituted W/W v mice (Table 1, Figure 4) .
While all of these findings support the hypothesis that, in this model of carcinogen-induced tumorigenesis, mast cells can contribute to tumor development and/or growth, other possible explanations of the findings cannot formally be ruled out. Reconstitution of W/W v mice by i.v. injection of Figure 5 The In addition to resulting in a profound mast cell deficiency, a moderate anemia, white coat color and sterility, the markedly reduced c-kit function in W/W v mice also results in a virtual lack of interstitial cells of Cajal. [36] [37] [38] [39] Consequently, W/W v mice have abnormal intrinsic electrical activity in the intestine. [36] [37] [38] [39] While effects of abnormalities in intrinsic electrical activity in the intestine on responses to DMH have not been reported, it is possible that such abnormalities may have influenced our results. For example, the abnormality in intestinal motility may increase contact of the feces with the mucosa, thereby promoting tumor development. 40 By contrast, the lower mechanical forces in the colon might decrease traction on existing tumors. On the other hand, in humans, constipation has not been reported to influence the incidence of colonic tumor development. 41 Whatever the potential effects of the abnormalities of intestinal motility on DMH-induced colon tumor development in W/W v mice, we think that it is unlikely that these effects significantly influenced the results obtained in our study. The transfer of bone marrow cells from þ / þ mice should have had no effect on the deficit in interstitial cells of Cajal in W/W v mice, as these cells are not of hematopoietic origin, yet the injection of þ / þ bone marrow cells virtually normalized the response of W/W v mice to the tumor-inducing effects of DMH (Table 1, Figure 4) .
If mast cells do contribute to the development of colonic tumors in response to injection of DMH, by what mechanism(s) might they have this effect? One possibility is that proteases released from mast cells, such as tryptases or chymases, mediate proangiogenic effects, as has been proposed in the setting of skin carcinogenesis. 10 Previous work has shown that the administration of certain protease inhibitors to mice can reduce their susceptibility to tumor formation in response to DMH. 42, 43 However, no evidence was presented in those studies showing that these agents were active because of effects on mast cell-derived proteases. Finally, in addition to releasing mediators, mast cells also can take up biologically active molecules from their environment via endocytosis, and thereby limit the biological activity of such products. 44 This finding raises the possibility that some of the functions of mast cells in tumor biology may be independent of the cells' ability to respond to local activating signals by degranulation and/or other mechanisms of mediator secretion.
In summary, our results show that the mutations affecting c-kit in W/W v mice markedly reduce the susceptibility of these mice to the development of DMH-induced colonic tumors. Moreover, our experiments with þ / þ bone marrow-reconstituted W/W v mice indicate that effects of c-kit on bone marrow-derived cells contribute significantly to the reduced susceptibility of the c-kit mutant W/W v mice to DMH-induced colonic tumors. Because transplantation of wild-type bone marrow cells into W/W v mice not only results in the development of mast cells in the recipients, but eventually can result in the entire hematopoietic system of the recipient mice becoming wild type in origin, our data do not prove that the key hematopoietic cell that enhances susceptibility to DMH in this system is the mast cell. Nevertheless, our findings are consistent with the possibility that mast cells can contribute to the susceptibility of mice to DMH-induced colonic epithelial neoplasms.
